Level of HaemSTAR involvement indicated by number of supported sites and number of patients recruited. The studies included MASCOT (a study assessing morbidity and portal circulation in patients with myeloproliferative neoplasms and splanchnic vein thrombosis), TRAIT (real world effectiveness of thrombopoietin receptor agonists in the management of immune thrombocytopenia (ITP) in the UK), FLIGHT (first line treatment pathways for newly diagnosed ITP) and the flash-mob audit of intravenous immunoglobulin use in ITP.
| Study | Type of study | Total number of sites | HaemSTAR supported sites (%) | Total number of patients | HaemSTAR supported patient recruitment (%) |
|---|---|---|---|---|---|
| MASCOT (pilot) | Retrospective | 6 | 6 (100%) | 31 | 31 (100%) |
| FLIGHT | Phase III prospective randomised controlled trial | 39 | 17 (44%) | 124 | 54 (44%) |
| TRAIT | Phase IV retrospective | 15 | 8 (53%) | 268 | 104 (39%) |
| Flash-mob audit | Retrospective national audit | 39 | 39 (100%) | 978 | 978 (100%) |